Effectiveness of the PCV13 in Older Thai Adults
Key facts
- Who runs it
- Mahidol University
- Where
- Thailand1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 825 people enrolled
- Started
- 5 Feb 2024
- Ended
- 30 Jan 2025
- Type of study
- Observational
- Record updated
- 9 May 2025
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- Prospective collection For case
- Thai older adults aged ≥60 years with or without health conditions diagnosed with culture confirmed pneumococcal community acquired pneumonia during 2012 - 2024
- Be given treatment either in-hospital admission or out-patient visiting hospital
- They ensure their PCV13 status (either received or not received is acceptable)
- Willing to participate in the study by their own decision or as a legal guardian; For matched control
- Thai older adults aged ≥60 years with or without health conditions diagnosed with non-pneumococcal community acquired pneumonia by doctor in-charge during 2012 - 2024
- Be given treatment either in-hospital admission or out-patient visiting in the same hospital with matched-case
- They ensure their PCV13 status (either received or not received is acceptable)
- Willing to participate in the study by their own decision or as a legal guardian; Retrospective collection For case
- Thai older adults aged ≥60 years with or without health conditions diagnosed with culture confirmed pneumococcal community acquired pneumonia during 2012 - 2024
- Be given treatment either in-hospital admission or out-patient visiting hospital
- Certain documented PCV13 status (either received or not received is acceptable)
- Recorded ICD: J13; For matched control
- Thai older adults aged ≥60 years with or without health conditions diagnosed with non-pneumococcal community acquired pneumonia by doctor in-charge during 2012 - 2024
- Be given treatment either in-hospital admission or out-patient visiting in the same hospital with matched-case
- Certain documented PCV13 status (either received or not received is acceptable)
- Recorded ICD: J09-18 (except J13)
Who cannot take part
- Unable to collect confirmed pneumococcal samples from microbiology laboratory; For control
- For case
- Unknown PCV13 status/history
- Timing between PCV13 and the onset of community acquired pneumonia <14 days
- Unknown PCV13 status/history
- Timing between PCV13 and the onset of community acquired pneumonia <14 days
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is the matched 1:2 case-control study, prospectively collect case and control who are diagnosed with pneumococcal or non-pneumococcal community acquired pneumonia (CAP), accordingly from November 2023 through October 2024. The investigators define a CASE as a person aged ≥60 years due to pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge. While a CONTROL is defined as a person aged ≥60 years due to non-pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge.
Read full original descriptionShow less
The goal of this observational study is to evaluate the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) in pneumococcal CAP in Thai adults aged ≥ 60 years with or without any medical conditions.
The main questions it aims to answer is:
• What are the effectiveness of PCV13 for preventing all typed, vaccine typed, or non-vaccine typed of pneumococcal CAP among Thai older adults?
The investigators retrospectively collect cases and control who are diagnosed with CAP accordingly from January 2012 through October 2023. The investigators define case and control the same as prospective method, but all data were retrieved from archive database.
-The investigators select a 1:2 matched control with criteria as follows; 10-year-interval of age, ward (the same patient care such as out or in-patient, or admitted in the same level ward).
Participants will be
* collated from hospital database regarding their CAP illnesses by pneumococcal and non-pneumococcal pneumonia condition. * explored their vaccine status by either vaccine book checking or hospital database.
Researcher will compare the effectiveness of PCV13 to prevent all typed, vaccine typed and non-vaccine typed pneumococcal pneumonia.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effectiveness of the 13-Valent Pneumococcal Conjugated Vaccine Against Community-Acquired Pneumonia in Older Thai Adults: A Matched Case-Control Study.
- Record updated
- 9 May 2025